{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:46:42Z","timestamp":1786121202272,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.autrev.2026.104126","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:13:06Z","timestamp":1782774786000},"page":"104126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rethinking immunosuppression in limited cutaneous systemic sclerosis. The lcSSc conundrum; pros and cons for a timely immunosuppressive treatment"],"prefix":"10.1016","volume":"25","author":[{"given":"Veronica","family":"Batani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Del Galdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2026.104126_bb0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","volume":"84","author":"Del Galdo","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104126_bb0010","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5301\/jsrd.5000216","article-title":"Limited cutaneous systemic sclerosis: the unfairly neglected subset","volume":"1","author":"Allanore","year":"2016","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.autrev.2026.104126_bb0015","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/ard-2024-226429","article-title":"Results from the international collaborative systematic literature review informing the 2023 EULAR recommendations for the treatment of systemic sclerosis","volume":"84","author":"Lescoat","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104126_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102452","article-title":"Outcomes of limited cutaneous systemic sclerosis patients: results on more than 12,000 patients from the EUSTAR database","volume":"19","author":"Frantz","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104126_bb0025","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104126_bb0030","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/art.38390","article-title":"Prediction of pulmonary complications and long-term survival in systemic sclerosis","volume":"66","author":"Nihtyanova","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2026.104126_bb0035","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.autrev.2014.08.029","article-title":"Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients\u2019 population and review of the literature","volume":"13","author":"Ferri","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104126_bb0040","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaf264","article-title":"Lung function and skin fibrosis changes as predictors of survival in SSc-associated interstitial lung disease: a EUSTAR study","author":"Sobanski","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2026.104126_bb0045","doi-asserted-by":"crossref","first-page":"e785","DOI":"10.1016\/S2665-9913(22)00217-X","article-title":"Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort","volume":"4","author":"Elhai","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2026.104126_bb0050","doi-asserted-by":"crossref","first-page":"127","DOI":"10.5301\/jsrd.5000239","article-title":"Early accrual of organ damage in systemic sclerosis: rationale for development of a disease damage index","volume":"2","author":"Tay","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.autrev.2026.104126_bb0055","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1136\/annrheumdis-2018-214764","article-title":"Development and validation of the scleroderma clinical trials consortium damage index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis","volume":"78","author":"Ferdowsi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104126_bb0060","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/acr.24873","article-title":"Damage trajectories in systemic sclerosis using group-based trajectory modeling","volume":"75","author":"Barbacki","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2026.104126_bb0065","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1093\/rheumatology\/kead002","article-title":"Prediction of damage trajectories in systemic sclerosis using group-based trajectory modelling","volume":"62","author":"Baron","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104126_bb0070","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/acr.25467","article-title":"Immunosuppressive drugs in early systemic sclerosis and prevention of damage accrual","volume":"77","author":"Baron","year":"2025","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2026.104126_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004333","article-title":"Does therapy with immunosuppressive drugs improve gastrointestinal symptoms in patients with systemic sclerosis?","volume":"10","author":"Stamm","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2026.104126_bb0080","article-title":"Mycophenolate Mofetil treatment reduces the risk of treatment escalation due to vascular complications in limited cutaneous systemic sclerosis: emulation of a target trial from Italian rheumatology society spring registry","author":"De Lorenzis","year":"2025","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2026.104126_bb0085","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1093\/rheumatology\/keae532","article-title":"Long-term retention rate, adverse event temporal patterns and rescue treatment strategies of mycophenolate mofetil in systemic sclerosis: insights from real-life","volume":"64","author":"De Lorenzis","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2026.104126_bb0090","first-page":"77","article-title":"A randomised open label pilot trial comparing mycophenolate mofetil with no immunosuppression in limited cutaneous systemic sclerosis (MINIMISE-Pilot)","author":"Denton","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2026.104126_bb0095","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keag108","article-title":"A randomised open label pilot trial comparing mycophenolate mofetil with no immunosuppression in limited cutaneous systemic sclerosis (MINIMISE-pilot)","author":"Denton","year":"2026","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104126_bb0100","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/thorax-2023-220541","article-title":"Phenotyping by persistent inflammation in systemic sclerosis associated interstitial lung disease: a EUSTAR database analysis","volume":"78","author":"Guler","year":"2023","journal-title":"Thorax"},{"key":"10.1016\/j.autrev.2026.104126_bb0105","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/art.43120","article-title":"Serum type I interferon score for prediction of clinically meaningful disease progression in limited cutaneous systemic sclerosis","volume":"77","author":"Di Donato","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2026.104126_bb0110","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.autrev.2017.12.010","article-title":"Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review","volume":"17","author":"Thiebaut","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104126_bb0115","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1002\/art.38029","article-title":"Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis","volume":"65","author":"Lef\u00e8vre","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104126_bb0120","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1378\/chest.130.1.182","article-title":"Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension","volume":"130","author":"Sanchez","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2026.104126_bb0125","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1164\/rccm.202009-3481OC","article-title":"Safety and efficacy of B-cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension: a multicenter, double-blind, randomized, placebo-controlled trial","volume":"204","author":"Zamanian","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"suppl 9","key":"10.1016\/j.autrev.2026.104126_bb0130","article-title":"Immunosuppression with targeted therapies reduces morbidity and mortality in pre-capillary pulmonary hypertension associated with systemic sclerosis: a EUSTAR analysis","volume":"75","author":"Bruni","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2026.104126_bb0135","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.autrev.2013.05.002","article-title":"Systemic sclerosis at the crossroad of polyautoimmunity","volume":"12","author":"Elhai","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2026.104126_bb0140","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3899\/jrheum.090815","article-title":"Associated autoimmune diseases in systemic sclerosis define a subset of patients with milder disease: results from 2 large cohorts of European Caucasian patients","volume":"37","author":"Avouac","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2026.104126_bb0145","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/23971983231155948","article-title":"Systemic sclerosis and primary biliary cholangitis: longitudinal data to determine the outcomes","volume":"8","author":"Lepri","year":"2023","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.autrev.2026.104126_bb0150","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1002\/art.21922","article-title":"Systemic sclerosis\u2013associated Sj\u00f6gren\u2019s syndrome and relationship to the limited cutaneous subtype: results of a prospective study of sicca syndrome in 133 consecutive patients","volume":"54","author":"Avouac","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2026.104126_bb0155","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/rheumatology\/kep368","article-title":"Genetic background of systemic sclerosis: autoimmune genes take centre stage","volume":"49","author":"Allanore","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2026.104126_bb0160","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/S2665-9913(20)30007-2","article-title":"Randomised controlled trials in systemic sclerosis: patient selection and endpoints for next generation trials","volume":"2","author":"Del Galdo","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2026.104126_bb0165","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis\u2013associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2026.104126_bb0170","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1093\/rheumatology\/keac512","article-title":"Survival and prognostic factors from a multicentre large cohort of unselected Italian systemic sclerosis patients","volume":"62","author":"Cacciapaglia","year":"2023","journal-title":"Rheumatology (Oxford)"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226001400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T03:03:31Z","timestamp":1786071811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226001400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1568997226001400"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104126","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rethinking immunosuppression in limited cutaneous systemic sclerosis. The lcSSc conundrum; pros and cons for a timely immunosuppressive treatment","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104126","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104126"}}